Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Dermatologic 2

Conditions

Skin Neoplasms 2Melanoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × talabostat × Clear all
NCT00080080 2007-06-08

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Point Therapeutics

Phase 2 Completed
Thoracic

Lung Neoplasms

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

NCT00083252 2007-06-08

Study of Talabostat and Cisplatin in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

NCT00290017 2007-06-08

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Point Therapeutics

Phase 3 Terminated
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡